Corden Pharma - A Full-Service CDMO’s Post

Want to learn more about the application of flow chemistry and PAT in crystallization process development within a CDMO environment? Join our scientific experts presenting posters at the BOSS XVIII symposium in Liège, Belgium, where we are proud to be Gold sponsor!   Today, come and discuss with Dr. Clemens Horn about the benefits of Flow Chemistry.  Tomorrow and Thursday, discuss with Dr. Tobias Wedel about the benefits of developing robust crystallization processes with the help of PAT.   #BOSS_Symposium #BOSSXVIII #flowchemistry #crystallisation #cdmo 

Dr. Mimoun Ayoub, Ph.D., Senior VP, Global Head of Sales & Key Account Management, discusses our broad CDMO capabilities to supply complex modalities such as small to large-scale peptides (including GLP-1s), lipids and oligos, as well as Lipid NanoParticle (LNP) formulation, sterile injectable drug products, and our extensive capacity of small molecule APIs & Drug Products, both highly potent and regular potency for Oral Solid Dosage. Learn more about our six technology platforms and how we support you in delivering complex modalities to your patients: https://lnkd.in/ejrr4frU #cordenpharma #cdmo #pharma #pharmaceuticals #drugdiscovery #drugdevelopment #pharmaceuticals #lipids #peptides #highlypotent #injectables #lnps

Summer Events Initiative: Giving Back to Our Community At CordenPharma we believe in the importance of giving back to the community and in the power of making a positive impact, not just in our industry but in the society as a whole. Our summer events are the perfect occasion to do this! We're very proud to support twelve healthcare organizations with donations towards diverse diseases, in many of our business focus areas. These contributions are a way for us to participate meaningfully, in alignment not only with our values but also with our purpose. We are part of a community that prioritizes empathy, teamwork, and progress. Stay tuned for updates on our journey and the difference we are making together. Thank you for your continued support and for being part of this initiative. Together, we can make a difference! #CommunitySupport #HealthcareInitiative #GivingBack #CorporateResponsibility #SummerEvent #MakingADifference

> CordenPharma hosts the 2024 Swiss Fine Chemical Association annual meeting at our Liestal, Switzerland site! The SFCA is a group of Swiss CDMOs that meet annually at rotating locations of the member companies. This year, it was CordenPharma’s turn to host the meeting at our Liestal, CH site, organized by Managing Director Thomas Müller. On 13 June, CordenPharma invited attendees to join for an aperitif and networking dinner. The next day, on 14 June, Thomas Mueller was joined by CEO Michael Quirmbach, Associate Director of Sales Steffen Bira, and former Liestal Managing Director and long-time colleague Juerg Burger to host ~2 representatives from each member CDMO. A full program of inspirational speeches was organized, followed by a lively exchange amongst member companies. Speakers and topics included: · Jade Sternberg of digitalswitzerland presented a talk on “The power of ecosystems to digitally transform a country – a perspective from Switzerland’s leading digital association.” · Felix Georg Mueller of plus10 presented a talk on “Intelligent efficiency increase in pharma production lines though GMP-compliant AI software tools.” · Francesco Crivelli of CSEM spoke on “AI for predictive analytics, in maintenance and quality control.” Thomas Mueller commented, “We had an engaging dinner and full program of interesting topics impacting the CDMO landscape. It was great to welcome member companies to this event to network, exchange ideas, and as we do every year, have discussions on trends. This year we organized very informative talks on the game-changing topics of digitalization and AI that not only affect the future of pharma in Switzerland, but globally as well. We look forward to future meetings at other SFCA member locations to come!”   #SFCA #swisschemicals #cdmo #pharmamanufacturing #pharmaceuticals #CordenPharma #digitalization #AI #predictiveanalytics #supplychain

> Press Release 19 June: WACKER & CordenPharma are pleased to announce their joint consortium has officially entered the pandemic readiness state as of 1 June 2024. Following a successful expansion and qualification phase, the companies are now in stand-by phase for at least five years. In the event of a new pandemic, WACKER and CordenPharma have taken the necessary steps to produce 80 million vaccine doses a year within an extremely short time, with most of the production steps taking place in Germany, and every production step occurring within the European Union. As part of the consortium, CordenPharma is ready to manufacture custom and standard lipids in our Frankfurt (DE) and Chenôve (FR) sites, as well as provide aseptic fill & finish and packaging of the chosen mRNA-based vaccine at our Caponago (IT) facility. In its site in Halle (Germany), WACKER will produce plasmid DNA (pDNA), which is an essential starting material for the manufacture of mRNA. Dr. Michael Quirmbach, CEO of CordenPharma Group, commented: “Obtaining the official confirmation of pandemic readiness by the German government is a major milestone for CordenPharma. I am extremely proud of our teams across the CordenPharma sites involved in establishing and delivering our pandemic readiness plan on schedule. We are now ready, together with our partner WACKER, to manufacture end-to-end mRNA-based vaccines for the German government and other customers.” “We have expanded our Halle site into a Competence Center for mRNA production,” said WACKER CEO Dr. Christian Hartel. “WACKER has invested over 100 million Euros in this expansion and created over 100 highly qualified jobs. Our expertise in making mRNA and LNPs will contribute to the fight against future pandemics. Together with CordenPharma, we are proud to serve the German government in its pandemic preparedness plans.” Read the full press release here: https://lnkd.in/d6vBdaPK #CordenPharma #wacker #pandemic #mrna #pdna #lipids #injectables #fillfinish #pharmaceuticals #vaccine #germany

We would like to welcome Stephan Haitz, Chief Commercial Officer, to the CordenPharma team! #cordenpharma  #cdmo #leadership #apis #drugproducts #drugpharmaceuticals #pharmaceuticalindustry

Join our team at Interphex Japan from June 26 to 28 at booth 20-9! Discover how we support biotech & pharma innovators of complex modalities in the advancement of their drug development lifecycle, providing reliable development and manufacturing of high quality APIs, Drug Products, and Lipid Excipients. #cordenpharma #interphex #interphex2024 #interphexjapan #cdmo #pharmaceuticals #pharmaindustry #drugdevelopment

Umberto Romeo, Development Director of the Lipid Nanoparticle Manufacturing area at our facility in Caponago (IT), explains how the kits support researchers and developers with the essential components needed to create and optimize their own LNPs for #mRNA delivery. The benefits of our kits include: -Customization and optimization of lipid composition and formulation parameters tailored to specific mRNA-based therapeutics -Cost effectiveness -Rapid prototyping -Intellectual property control Take advantage of our 25% discount by ordering our kits before the end of June 2024. Order here: https://lnkd.in/eTK2ZSPj #cordenpharma #lipidnanoparticles #lnps #cdmo #pharmaceuticals #pharma #pharmaindustry

> PR 6 June 2024: CordenPharma & Certest Pharma Partner to Unleash the Potential of Patented Ionizable Lipids in LNP Formulation. The partnership, signed on 7 May 2024, aims to add ionizable lipids to CordenPharma’s complex LNP formulation services, the key element needed to close the gap in our formulation offering to support biotech and pharmaceutical companies with the development, discovery, and manufacturing of xRNA / xDNA from early clinical phase to commercial. Under the terms of the agreement, Certest will provide access to their unique ionizable lipids platform and CordenPharma will leverage cGMP manufacturing capacities, regulatory know-how, and market access to ensure high-quality GMP supply for our customers’ journey to market. Matthieu Giraud, PhD, CordenPharma’s Senior Director, Global Lipids & Carbohydrates Platform, commented: “At CordenPharma, we independently consider each of the four lipid functional excipients of an LNP formulation to provide our customers with the most effective support in solving their therapeutic formulation challenges. This partnership augments our offer with a lean and attractive approach to LNP formulation that also reduces the growing IP challenges in the market.” Nelson Fernandes, CEO of Certest, commented: “The world of lipid nanoparticles is revolutionizing the pharmaceutical industry today. At Certest, we offer a powerful delivery platform, thanks to our ionizable lipids, that will enable clients to overcome nearly all therapeutic challenges. This collaboration is going to be a significant advancement for our clients.” Read the full press release here > https://lnkd.in/evjJzmJm #CordenPharma #certest #lipidnanoparticles #lnps #lipids #mRNA #xDNA #ionizablelipids #lnpformulation #cdmo #pharmaceuticals #vaccinemanufacturing #peptides #lnpdrugdelivery